Editorial
doi: 10.1016/j.ejca.2004.09.019.
Fulvestrant--ready to start its journey in the breast cancer adjuvant endocrine world?
- PMID: 15691631
- DOI: 10.1016/j.ejca.2004.09.019
Item in Clipboard
Editorial
Fulvestrant--ready to start its journey in the breast cancer adjuvant endocrine world?
Eur J Cancer.
2005 Feb.
No abstract available
Comment on
-
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.Eur J Cancer. 2005 Feb;41(3):346-56. doi: 10.1016/j.ejca.2004.07.035. Eur J Cancer. 2005. PMID: 15691633 Review.
Similar articles
-
Clinical value of fulvestrant in breast cancer.Clin Breast Cancer. 2005 Apr;6 Suppl 1:S4. doi: 10.3816/cbc.2005.s.007. Clin Breast Cancer. 2005. PMID: 15865848 No abstract available.
-
Endocrine therapy for the treatment of postmenopausal women with breast cancer.Expert Rev Anticancer Ther. 2009 Feb;9(2):187-98. doi: 10.1586/14737140.9.2.187. Expert Rev Anticancer Ther. 2009. PMID: 19192957 Review.
-
Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.Eur J Oncol Nurs. 2004;8 Suppl 2:S83-8. doi: 10.1016/j.ejon.2004.09.007. Eur J Oncol Nurs. 2004. PMID: 15590319 Review.
-
Fulvestrant antiestrogen for treatment of breast cancer.Clin J Oncol Nurs. 2003 Mar-Apr;7(2):201-2. doi: 10.1188/03.CJON.201-202. Clin J Oncol Nurs. 2003. PMID: 12696217 Review.
-
Fulvestrant ('Faslodex'): extending the reach of endocrine therapy?Breast Cancer Res Treat. 2005;93 Suppl 1:S1-2. doi: 10.1007/s10549-005-9035-5. Breast Cancer Res Treat. 2005. PMID: 16247593
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
